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ABSTRACT 
Perchloroethylene (PER) is a degreasing solvent widely 
used to replace the toxic trichloroethylene. However, PER 
can also lead to nephrotoxicity via bioactivation by the 
glutathione (GSH) conjugative pathway. In this study, a 
postcolumn o-phtaldialdehyde (OPA)/N-acetylcysteine 
(NAC) derivatisation method has been developed and 
compared to existing methods for analysis of PER GSH 
conjugates. Subsequently, the rate of this conjugation has 
been studied for the first time in human subcellular 
fractions. The specific activity of PER GSH conjugation in 
humans shows significant interindividual differences and 
is 10-fold lower compared to rats, indicating that humans 
are less susceptible to nephrotoxicity via this pathway.  
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INTRODUCTION 
Tetrachloroethylene or perchloroethylene (PER) is a 
volatile and colourless solvent and is widely used as a 
metal degreasing agent or cleaning solvent in the textile 
industry11,13.Occupational exposure has decreased due to 
technological advances in dry cleaning and degreasing 
methods in the USA and Europe5. However, exposure is 
still common in developing countries and the widespread 
use has resulted in environmental contamination of water, 
soil and food5,13. The relatively similar compound 
trichloroethylene (TRI) has been identified as a Substance 
of Very High Concern and requires authorisation before it 
is used since 20163. This regulation has not been enforced 
for PER, which is a potential alternative to TRI and still 
widely used by professional workers. Moreover, PER has 
been found to have an even higher correlation with renal 
injury compared to TRI9. 
Bioactivation 
PER nephrotoxicity is the result of metabolism via the 
glutathione (GSH) conjugative pathway. In this pathway, 
PER is conjugated to GSH by Glutathione S-Transferases 
(GSTs) in the liver to form S-(1,2,2-trichlorovinyl)-l-
glutathione (TCVG) (Figure 1)2,9. TCVG is transported to 
the kidney, where it is rapidly hydrolysed by γ-
glutamyltransferase (GGT) and cysteinylglycine 
dipeptidase to form S-(1,2,2-trichlorovinyl)-l-cysteine 
(TCVC)2,8. 
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In the kidney, TCVC can be detoxified to urinary excreted 
products, this reaction can also proceed vice versa. 
However, TCVC can also be converted in the kidneys by 
β lyase to dichlorothioketene (DCTK) via a thiol. It is this 
product which subsequently leads to nephrotoxicity as it 
can bind to proteins or DNA2,8,12. 
 
 
 
Figure 1 Metabolism of PER via the GSH conjugative 
pathway. S-(1,2-trichlorovinyl)-l-cysteine (TCVC) can be 
bioactivated by β lyase, which results in nephrotoxicity. 
 
GSH conjugation kinetics 
The rate of metabolism via this pathway, and thus the risk 
of nephrotoxicity, depends on the activity of GST. 
Previously, specific activities of GST have been 
determined in subcellular fractions of F344 rats9. The 
specific activity in male rat liver cytosol after 60 minute 
incubations with 2 mM PER and 5 mM GSH was 10.6 ± 
2.2 nmol/mg protein/60 minutes. However, this rate has 
not yet been determined for humans. Moreover, it is 
unknown which GST isoforms play a role in PER 
metabolism. At least seven GST classes exist, the human 
variants of these enzymes are described with A, M, P, S, 
T, O, and Z7. The genetically determined isoforms GSTT1, 
GSTP1 and GSTM1 are most extensively studied and 
hypothesised to contribute to environment-dependent 
diseases4,7. It is still unknown which isoforms of GST are 
involved in PER metabolism1. 
 
Analytical methods for detection of PER GSH 
conjugates 
In order to determine the rate of PER metabolism via this 
pathway and thus improve public health assessment, a 
sensitive analytical method is required. It has already been 
demonstrated for TRI that the large variation in 
experimental results is partly due to the difference in 
analytical methods14.  
 
In this study, a high performance liquid chromatography 
(HPLC) method with postcolumn o-phtaldialdehyde/n-
acetylcysteine (OPA/NAC) derivatisation technique will 
be optimised. OPA/NAC is an already established method 
for quantification of amino acids. In this derivatisation 
technique, the aldehydes in OPA react with NAC and with 
the N-terminal amino group of the glutathione conjugates 
(Figure 2). This product can be detected with fluorometry. 
Postcolumn OPA/NAC derivatisation has been applied 
previously and reached limits of detection of respectively 
3.88 µM and 9.2 µM 6,10  .  
 
 
  
Figure 2 Reaction of O-phtaldialdehyde and N-
acetylcysteine (OPA/NAC) with TCVG to the fluorescent 
derivatisation product which can be detected with 
fluorometry. 
 
Determination of the rate of PER metabolism via the GSH 
conjugative pathway in humans requires a sensitive 
analytical method and is essential for nephrotoxicity risk 
assessment. Therefore, the aim of this study is twofold. 
Firstly, sensitive analytical methods for detection of PER 
GSH conjugated metabolites will be optimised and 
compared. Secondly, the rate of GSH conjugation and 
further metabolism of PER will be analysed for the first 
time in human subcellular fractions and compared to 
metabolism in rats to determine interindividual and 
interspecies variability. 
 
METHOD 
Development of sensitive analytical method for TCVG 
analysis  
 
LC-MS analysis 
A dilution series of TCVG in 50 mM potassium phosphate 
buffer pH 7.4 was prepared and analysed with TOF LC-MS 
6230 Agilent Technologies, equipped with Luna 5 µm C18 
column (150x4 60 mm) in volumes of 300 µL with 30 µL 
10% perchloric acid. Eluents A (99% water, 0.2% formic 
acid, 0.8% acetonitrile) and B (99% acetonitrile, 0.2% 
formic acid, 0.8% water) were programmed with the 
following gradient: 0 min: 3% B, 5 min: 3% B, 25 min: 53% 
B, 28 min: 99%, 30 min: 99%, 31 min: 3% B, 35 min: 3% 
B. The flow rate was set to 0.5 mL/min and samples were 
injected at a volume of 50 µL. 
 
HPLC analysis with UV/VIS 
A dilution series of TCVG was prepared in 50 mM 
potassium phosphate buffer pH 7.4. To each 300 µL of 
sample, 30 µL of 10% perchloric acid was added prior to 
HPLC analysis. The HPLC system was equipped with a 
Luna 5µm C18 column (150x4 60 mm), Gilson 234 
autoinjector, two Gilson 305 pumps, Shimadzu UV/VIS 
detector SPD-20A (response 4, lamp 1, aux range 2, range 
1). Eluents A (99% water, 0.2% formic acid, 0.8% 
acetonitrile) and B (99% acetonitrile, 0.2% formic acid, 
0.8% water) were run according to the following gradient: 0 
min: 3% B, 5 min: 3% B, 25 min: 53% B, 28 min: 99%, 30 
min: 99%, 31 min: 3% B, 35 min: 3% B. TCVG was detected 
with UV/VIS analysis at 265 nm. 
 
HPLC with postcolumn OPA/NAC derivatisation 
A dilution series of TCVG was prepared in 50 mM 
potassium phosphate buffer pH 7.4. To 300 µL of each 
dilution was added 30 µL 10% perchloric acid in HPLC vials 
prior to analysis. OPA/NAC reagent was prepared with 100 
mg/L OPA (Sigma Aldrich) (0.75 M) and 122 mg/L NAC 
(Sigma Aldrich) (0.75 M) in 0.1 M Borate buffer pH 10.8.  
 
 
 
The dilution series was analysed with a HPLC system 
equipped with Gilson 234 autoinjector, two Gilson 305 
pumps, Luna 5 µm C18 column (150x4 60 mm), Solvent 
delivery system 400 from Applied Biosystems, Shimadzu 
UV/VIS detector SPD-20A and Shimadzu fluorescence 
detector RF-10Axl. Eluents A (99.05% water, 0.1% formic 
acid, 0.85% acetonitrile) and B (99.05% acetonitrile, 0.1% 
formic acid, 0.85% water) were run according to the 
following gradient: 0 min: 3% B, 5 min: 3% B, 25 min: 53% 
B, 28 min: 99%, 30 min: 99%, 31 min: 3% B, 35 min: 3% 
B. OPA/NAC reagent was added postcolumn at a flow rate 
of 0.6 mL/min. The reaction was subsequently allowed to 
take place in a reaction coil (1 mL), heated to 50 °C. The 
resulting flow was analysed in the fluorophotometer at 
excitation wavelength 345 nm and emission at 455 nm and 
with UV/VIS at wavelength 345 nm. 
 
Incubation of human and rat liver factions with PER 
Work solution was prepared with 5 mM GSH (Sigma 
Aldrich) and 2,5 mM PER (Baker Chemicals B.V.) (stock 
solution in acetonitrile (VWR chemicals), final 
concentration 1%) in 50 mM potassium phosphate buffer pH 
7.4. Stop reagent consisted of 1 mM phenylalanine (Janssen 
Chimica) in 10% perchloric acid (sample S1329-S1449) or 
1 mM 2,2-DCVG in 10% perchloric acid (sample S1336-
R1341). All solutions were placed on ice. For each 
incubation, 250 µL enzyme fraction was added to 750 µL 
work solution. Samples were incubated at 30 °C for 2 hours. 
Following incubation, all samples were placed back on ice 
and 110 µL stop reagent with internal standard was added. 
Subsequently, samples were vortexed and centrifuged for 15 
minutes at 14.000 rpm. Of each supernatant, 300 µL was 
transferred to vials for LC-MS analysis. 
 
Determination of protein concentration in liver cytosol 
fractions 
A dilution series of Melford Albumine Bovine Fraction 
(BSA) with concentrations 1, 0.8, 0.6, 0.4, 0.2 and 0 mg/mL 
was prepared as protein concentration reference. All 
subcellular fractions were diluted 100x in 50 mM potassium 
phosphate buffer pH 7.4. For each measurement, 20 µL 
diluted enzyme fraction or BSA solution was added to 1 mL 
Bio-Rad Protein Assay Dye Reagent Concentrate, diluted 
10x in water. After 3 minutes an extinction spectrum from 
500 to 900 nm was measured with UV/VIS 
Spectrophotometer Ultrospec 2100 pro (Amersham 
Biosciences). 
 
Incubations of human and rat liver- and kidney fractions 
with TCVG 
Stock solution was prepared with 100 µM TCVG and 1 mM 
diglycine (cofactor GGT) in 50 mM potassium phosphate 
buffer pH 7.4. Stop solution was also prepared from 1 mM 
phenylalanine (internal standard) and 10% perchloric acid in 
50 mM potassium phosphate buffer pH 7.4. All solutions 
were stored on ice. For each incubation, 50 µL enzyme 
fractions were added to 500 µL stock solution. Samples were 
incubated for 30 minutes at 37 °C. Subsequently, samples 
were placed back on ice and 60 µL stop solution was added 
to each sample. Samples were then vortexed and centrifuged 
for 15 minutes at 14.000 rpm. Of each supernatant, 300 µL 
was transferred to vials and analysed with the described LC-
MS method. 
 
RESULTS 
 
Comparison of analytical methods and their limits of 
detection 
With LC-MS, TCVG peaks were observed after 23.5 
minutes at masses of 436 : 438 : 440 with relative frequency 
3 : 3 : 1. The resulting integrated peaks with mass 436 could 
be measured until concentrations of 90 nM and provide the 
following calibration curve (Figure 4):  
 
AUC=149587[TCVG in µM]-2900.0 (R2=0.9989) 
 
Analysis with the optimised HPLC and UV/VIS detection 
method shows peaks for TCVG after 21.5 minutes, with 
detection limit 0.5 µM and the following concentration 
dependency (Figure 4):  
 
AUC=1407[TCVG in µM]+1208 (R2=0.997) 
 
The developed and optimised postcolumn OPA/NAC 
derivatisation method showed a relatively unstable baseline 
signal and small, broad peaks at similar TCVG 
concentrations. The chromatogram obtained for 50 µM 
TCVG and 50 µM DCVG is shown in Figure 3.  
 
 
Figure 3 Fluorometric chromatogram section from 10.0 to 
25.0 minutes for 100 µM TCVG and 100 µM DCVG as 
internal standard (IS) 
 
TCVG peaks were observed after 22.3 minutes and could be 
observed until 4 µM with the following concentration 
dependency (Figure 4): 
 
AUC=698.19[TCVG in µM]-277.76 (R2=0.9946) 
  
Thus, the new postcolumn OPA/NAC derivatisation method 
developed in this study did not improve the detection limit 
compared to HPLC analysis without derivatisation. The LC-
MS method with a limit of detection of 90 nM was most 
sensitive and used to analyse incubation samples.  
 
 
Figure 4 Comparison of LC-MS, HPLC-UV/VIS and 
postcolumn OPA/NAC methods 
 
Specific activity of TCVG formation in human liver 
cytosol 
After 2 hour incubations with 2.5 mM PER and 5 mM GSH 
at 30 °C and LC-MS analysis, TCVG peaks were detected. 
Peaks with mass 436 were integrated and the TCVG 
concentration was determined with the aid of the calibration 
line obtained in Figure 4. The protein concentration was 
determined with the described BSA assay. First, a 
calibration curve with the relation between absorption at 595 
nm and protein concentration in mg/mL was measured for 
BSA. This standard curve has the following formula: 
 
Abs=0.7761 [BSA in mg/ml]+0.545 (R^2=0.9112) 
 
With the aid of this calibration curve, protein concentrations 
in human liver cytosol fractions were determined. The 
concentration TCVG in nM formed in 120 minutes, and the 
protein concentration in mg/ml were used to calculate the 
specific activity. The specific activity of PER metabolism to 
TCVG in 20 human liver cytosol fractions is displayed in 
Figure 5.  
 
 
Figure 5 Specific activity of PER metabolism to TCVG in 
pmol/mg protein/60 minutes in 20 human liver cytosol 
fractions and two rat liver cytosol fractions (PB-induced 
(RLC_PB) and control (RLC_control)), obtained by 
dividing the TCVG concentrations after 120 minute 
incubations by the protein concentrations. In rat samples, the 
specific activity was 10-fold higher compared to humans. 
Moreover, significant interindividual differences were 
observed between humans.  
 
Secondary metabolism of TCVG 
TCVG was incubated with liver and kidney fractions of 
humans and rats and subsequently analysed with LC-MS. 
TCVG was detected with mass 436. TCVGC was detected 
with mass 307, and TCVC with mass 250. Decrease in 
TCVG and increase in TCVGC and TCVC were expressed 
as a percentage of the AUC of TCVG in the blank sample 
(Figure 6). These findings confirm that further metabolism 
of TCVG takes place primarily in the kidney. Moreover, 
TCVG was not metabolised further in human liver cytosol 
or rat liver, indicating that these fractions could be used for 
incubations with PER to study the specific activity of GST 
enzymes in the liver responsible for PER metabolism.  
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Figure 6 Metabolism of TCVG to TCVGC and TCVC in 
human liver and kidney samples after incubations of human 
kidney and liver cytosol- and microsome fractions with 100 
µM TCVG during 30 minutes at 37°C. Shown is the decrease 
in TCVG (orange), increase in TCVGC (blue) and TCVC 
(purple), expressed as a percentage of AUC of TCVG in the 
blank sample. TCVG is not further metabolised in the liver 
cytosol fractions, but is primarily converted in the kidney.  
 
CONCLUSION 
A new postcolumn OPA/NAC derivatisation method has 
been developed for separation of GSH conjugates of PER 
with a limit of detection of 4 µM TCVG. This is in line with 
previous postcolumn OPA/NAC methods, which reached 
limits of detection of 4 µM and 9.2 µM6,10. However, the 
previously developed LC-MS method is still the most 
sensitive method for TCVG analysis with a detection limit 
of 90 nM. With the aid of this method, a specific activity of 
PER GSH conjugation in rat liver cytosol of 83.9 ± 11.1 
pmol/mg protein/60 minutes was determined. This is 120-
fold lower than the value obtained previously by Lash et al.9 
and could be accounted for by the difference in analytical 
method applied. In a comparative study, it was found that the 
HPLC-UV method applied by Lash et al. is not selective for 
the DCVG analyte14. This non-specificity may lead to 
recoveries of up to 200-fold higher than the actual metabolite 
levels and could explain the previous overestimation of 
TCVG formation in rats. Moreover, the specific activity of 
TCVG formation has been studied for the first time in liver 
cytosol fractions of 20 different humans. Significant 
interindividual differences in TCVG formation were 
observed, indicating that specific GST isoforms may play a 
role in GSH conjugation of PER. Moreover, GSH 
conjugation of PER was 10-fold lower in humans compared 
to rats, which suggests that humans are less susceptible to 
nephrotoxicity via this pathway. It was also confirmed that 
further metabolism of TCVG to TCVC takes place primarily 
in the kidney, and was not observed in human liver cytosol. 
Determination of the specific GST isoforms which catalyse 
TCVG formation and their kinetic parameters in future 
research could improve our understanding of the importance 
and interindividual variability of this pathway in humans, 
and thus the risk of nephrotoxicity. 
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